ArticleAvicenna journal of phytomedicine
Preventive and therapeutic effects of
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cyclophosphamide (Cy) as an alkylating chemotherapeutic agent with broad-spectrum efficacy in cancer treatment. Despite its wide spectrum of clinical usage, off-target multiple organ toxicity such as sperm and testicular injury is one of its toxic side effects. Since the Materials and Methods: Forty-eight adult male Wistar rats were randomly allocated into eight groups (n=6): control, Cy [received a single dose of 75 mg/kg, intraperitoneal (i.p)], NOE+Cy (Prevention): received NOE 500 and 1000 mg/kg/day, orally for 21 consecutive days and on the last day received Cy, Cy+NOE (Treatment): received NOE 500 and 1000 mg/kg/day, orally for 7 days after Cy administration for 21 consecutive days, and NOE (500 and 1000 mg/kg/day). After experiments, the testicular weight and volume, testosterone level, and sperm parameters as well as histologic and histomorphometric changes of testis were examined. Results: Base on the results, Cy caused significant decreases in testicular weight and volume, decreased testosterone level and reduced sperm count, and motility whereas increased sperm abnormality (p<0.05). Cy significantly reduced seminiferous tubules diameter, and height of the seminiferous epithelium (p<0.05). Furthermore, disorganization of seminiferous tubules diameter was increased in Cy group (p<0.05). Interestingly, pre and post-treatment with NOE could effectively improve testicular weight and volume, and testosterone level as well as sperm parameters. Furthermore, NOE administration ameliorated seminiferous tubules diameter diameter, seminiferous epithelium height (p<0.05). Conclusion: It is concluded that NOE may provide a potential protective effect for Cy-induced testicular damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.